Form SC 13D/A METLIFE INC Filed by: BOARD OF DIRECTORS OF METLIFE INC

May 8, 2019 6:45 AM

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

AMENDMENT NO. 77 TO

SCHEDULE 13D

Under the Securities Exchange Act of 1934

 

 

MetLife, Inc.

(Name of Issuer)

Common Stock, par value $.01 per share

(Title of Class of Securities)

59156R108

(CUSIP Number)

Stephen W. Gauster

Executive Vice President and General Counsel

MetLife, Inc.

200 Park Avenue

New York, NY 10166-0188

(212) 578-9500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 7, 2019

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

   

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 2 of 9 Pages

 

  (1)   

Names of Reporting Persons                                    Board of Directors of MetLife, Inc., as an entity

 

I.R.S. Identification

Nos. of Above Persons                                                     Not applicable

  (2)  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☐

 

  (3)  

SEC Use Only

 

  (4)  

Source of Funds

 

    Not Applicable. See Item 4

  (5)  

Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

 

    ☐

  (6)  

Citizenship or Place of Organization

 

    U.S.A.

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

 

     (7)    

Sole Voting Power

 

    0

     (8)   

Shared Voting Power

 

    145,393,753*

     (9)   

Sole Dispositive Power

 

    0

   (10)   

Shared Dispositive Power

 

    0

(11)  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

    145,393,753*

(12)  

Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

    ☐

(13)  

Percent of Class Represented by Amount in Row 11

 

    15.3%

(14)  

Type of Reporting Person

 

    IC

 

*

Unless otherwise indicated, all information relating to beneficial ownership of the Shares by the Reporting Persons is as of April 30, 2019.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 3 of 9 Pages

Items 4 and 5 are amended and restated as set forth below:

ITEM 4. PURPOSE OF TRANSACTION.

The Board of Directors (the “Board”) is reporting beneficial ownership of 145,393,753 shares of Common Stock (the “Shares”) held by the MetLife Policyholder Trust (the “Trust”) under the Plan of Reorganization, dated September 28, 1999, as amended (the “Plan”), of Metropolitan Life Insurance Company (“MetLife”).

On April 7, 2000, 494,466,664 Shares were issued to the Trust pursuant to Section 5.2(d) of the Plan, a copy of which is attached as an exhibit to this statement. No consideration has been separately provided therefor by any member of the Board, except for Shares allocated to such member pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries (i) under the Purchase and Sale Program provided for by the Trust Agreement (as defined below), (ii) pursuant to the Issuer’s split-off of Reinsurance Group of America, Incorporated, in September 2008, and (iii) to withdraw Shares from the Trust, as well as escheatment of unclaimed Shares, have resulted in a decrease in the number of Shares held by the Trust from 494,466,664 to 145,393,753 (as adjusted to reflect refinements in the calculation of the number of Shares issued to the Trust under the Plan).

Under the Plan and the MetLife Policyholder Trust Agreement, dated as of November 3, 1999 (as amended, the “Trust Agreement”), by and among MetLife, the Issuer, Wilmington Trust Company (the “Trustee”) and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the “Custodian”), a copy of which is attached as an exhibit to this statement, certain eligible policyholders of MetLife (“Trust Eligible Policyholders”) have been allocated a number of interests in the Trust (“Trust Interests”) equal to the number of shares of Common Stock allocated to the Trust Eligible Policyholders in accordance with the Plan. The assets of the Trust principally are the Shares issued to the Trust for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the “Beneficiaries”). The Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian.

The Trust Agreement provides the Trustee with directions as to the manner in which to vote, assent or consent the Shares at all times during the term of the Trust. On all matters brought for a vote before the stockholders of the Issuer, with the exception of a Beneficiary Consent Matter (as defined below), the Trustee will vote in accordance with the recommendation given by the Board of the Issuer to its stockholders or, if no such recommendation is given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee will vote all of the Shares in favor of, in opposition to or abstain from the matter in the same ratio as the Trust Interests of the Beneficiaries that returned voting instructions to the Trustee indicated preferences for voting in favor of, in opposition to or abstaining from such matter. The Trust Agreement also contains provisions allowing Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares to participate in any tender or exchange offer for the Common Stock and to make any cash or share election, or perfect any dissenter’s rights, in connection with a merger of the Issuer.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 4 of 9 Pages

A “Beneficiary Consent Matter” is:

 

  (i)

a contested election of directors or, subject to certain conditions, the removal of a director,

 

  (ii)

a merger or consolidation, a sale, lease or exchange of all or substantially all of the assets or a recapitalization or dissolution of the Issuer, if it requires a vote of stockholders under applicable Delaware law,

 

  (iii)

any transaction that would result in an exchange or conversion of the Shares for cash, securities or other property,

 

  (iv)

issuances of Common Stock prior to the first anniversary of the effective date of the Plan (the “Effective Date”) at a price materially below the prevailing market price, if a vote is required to approve the issuance under Delaware law, other than issuances in an underwritten public offering or pursuant to an employee benefit plan,

 

  (v)

before the first anniversary of the Effective Date, any matter that requires approval by a vote of more than a majority of the outstanding stock of the Issuer entitled to vote thereon under Delaware law or the certificate of incorporation or the by-laws of the Issuer, and any amendment to the certificate of incorporation or by-laws of the Issuer that is submitted to a vote of stockholders for approval, and

 

  (vi)

proposals submitted to stockholders requiring the Board to amend the Issuer’s stockholder rights plan, or redeem rights under that plan, other than a proposal with respect to which the Issuer has received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. The Issuer does not currently have a stockholder rights plan.

The Trust Agreement contains provisions enabling the Beneficiaries to withdraw the Shares allocated to them under the Plan and the Trust Agreement for resale or otherwise and to receive dividends on such Shares.


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 5 of 9 Pages

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

 

(a)

As an entity, the Board of the Issuer beneficially owns 145,393,753 shares or 15.3% of the Issuer’s outstanding Common Stock. The Board of the Issuer is deemed to beneficially own the shares of Common Stock held by the Trust because the Board will direct the voting of these shares on certain matters submitted to a vote of stockholders. See Item 4.

 

(b)

As an entity, the Board of the Issuer has shared voting power with respect to 145,393,753 shares of Common Stock.

 

(c)

There were no transactions in the class of securities reported on that were effected by the Reporting Persons since February 14, 2019 other than transactions described in Item 4 which resulted in a decrease in the number of shares of Common Stock held by the Trust from 147,240,587 to 145,393,753.

 

(d)

The Beneficiaries of the Trust have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares allocated to them under the Plan and the Trust Agreement. See Item 4.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit 99.1 Joint Filing Agreement under Rule 13d-1(k)(1)

Exhibit 99.2 Power of Attorney


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 6 of 9 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Dated: May 7, 2019

 

*

Cheryl W. Grisé

    

*

Carlos M. Gutierrez

    

*

Gerald L. Hassell

    

*

David L. Herzog

    

*

R. Glenn Hubbard

    

*

Edward J. Kelly, III

    

*

William E. Kennard

    

*

Michel A. Khalaf

    

*

James M. Kilts

    

*

Catherine R. Kinney

    

*

Diana McKenzie

    

*

Denise M. Morrison

    


SCHEDULE 13D

 

CUSIP No. 59156R108   Page 7 of 9 Pages

 

                   * By    /s/ Stephen W. Gauster
    Stephen W. Gauster
    Attorney-in-fact

Exhibit 99.1

SCHEDULE 13D

 

CUSIP No. 59156R108   Page 8 of 9 Pages

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees that the Statement on Amendment No. 77 to Schedule 13D, to which this exhibit is attached, is filed on his or her behalf.

Dated: May 7, 2019

 

*

Cheryl W. Grisé

    

*

Carlos M. Gutierrez

    

*

Gerald L. Hassell

    

*

David L. Herzog

    

*

R. Glenn Hubbard

    

*

Edward J. Kelly, III

    

*

William E. Kennard

    

*

Michel A. Khalaf

    

*

James M. Kilts

    

*

Catherine R. Kinney

    

*

Diana McKenzie

    

*

Denise M. Morrison

    


SCHEDULE 13D

CUSIP No. 59156R108  

Page 9 of 9 Pages

 

                   * By    /s/ Stephen W. Gauster
    Stephen W. Gauster
    Attorney-in-fact

Exhibit 99.2

POWER OF ATTORNEY

RELATED TO AMENDMENTS TO SCHEDULE 13D

The undersigned hereby constitutes and appoints Stephen W. Gauster, Executive Vice President and General Counsel, John McCallion, Executive Vice President and Chief Financial Officer, and Edward Spehar, Executive Vice President and Treasurer, or any of them, and their respective successors from time to time in the offices of General Counsel, Chief Financial Officer, or Treasurer, as the case may be, as such person’s true and lawful attorney-in-fact and agent for such person and in such person’s name, place and stead, in any and all capacities, to sign individually and not collectively, (i) any and all amendments to a Schedule 13D with regard to the MetLife, Inc. Board of Directors’ beneficial ownership of securities of MetLife, Inc. (“Schedule 13D”), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and (ii) any and all other instruments which any of such attorneys-in-fact and agents deems necessary or advisable to comply with all applicable laws, rules and regulations in connection with the matters authorized by clause (i), and does hereby grant unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or any substitute therefor, may lawfully do or cause to be done by virtue hereof. The authority of Stephen W. Gauster, Executive Vice President and General Counsel, John McCallion, Executive Vice President and Chief Financial Officer, and Edward Spehar, Executive Vice President and Treasurer, or any of their respective successors from time to time in the offices of General Counsel, Chief Financial Officer, or Treasurer, as the case may be, under this Power of Attorney shall continue until the Board of Directors is no longer required to file amendments to the Schedule 13D, except that such authority shall be terminated with respect to such person whose signature appears below when such person revokes in writing the authority granted hereby. This Power of Attorney does not revoke any prior powers of attorney.

 

Signature:   /s/ Michel Khalaf
Name:   MICHEL KHALAF
Date:   May 1, 2019

Categories

SEC Filings